Solutions

• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery

OncoSolid™ Nasopharyngeal Cancer Organoid Model based CAR-T In Vitro Efficacy Assay Service

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Nasopharyngeal Carcinoma Organoid Models

Nasopharyngeal carcinoma is a dominant subset of head and neck cancer and presents a high incidence rate in populations. Radiation treatment is adopted for primary nasopharyngeal carcinoma deletion but is not effective for recurrent cases. Typical 2D cell models have limitations in reflecting the complex tumor tissue and hinder the study of tumor pathogenesis and recurrence and the development of novel effective anti-tumor reagents. Cancer organoid models are mini-tumor tissue that is cultured in vitro and recapitulates key characteristics and functions of organs. Due to increased clinical relevance, organoids are widely used for basic research and personal medicine.

Nasopharyngeal Carcinoma Organoid-models Mediated CAR-T Efficacy Test at Creative Biolabs

With cutting-in-edge organoid culture technologies, Creative Biolabs offers a living biobank of cancer organoid models for CAR-T anti-tumor efficacy tests in vitro. Our one-stop service includes organoid generation, organoid characterization, and organoid application in immunotherapy development.

Workflow

Fig.1 Working steps of CAR-T in vitro anti-tumor efficacy test with nasopharyngeal cancer organoid models. (Wang, et al., 2020)

Key Features

Organoid Characterization

Optimal Culture System

We have established an improved protocol to generate cancer organoids.

• The highly efficient enzymatic treatment process for tumor samples
• Optimized components and concentration of cytokines and growth factors for the organoid generation
• Decreased cost and simplified manipulation procedures

Nasopharyngeal Cancer-related CAR-T Products for Cytotoxicity Test

Organoids are versatile models to predict CAR-T in vivo anti-tumor efficacy. As a lead provider in immunotherapy development, we provide cancer-targeted, high-quality CAR-T products that can be directly applied to test cytotoxicity against cancer organoid models.

Creative Biolabs offers cancer organoids with high physiological relevance to facilitate CAR-T therapy development and in vivo efficacy analysis. Our service repertoire contains cancer epitope analysis, antigen-targeted immunotherapies development, in vitro and in vivo efficacy tests, etc. Please contact us for an optimized protocol for your cancer organoid study.

Reference

1. Wang, X. W.; et al. Establishment of a patient-derived organoid model and living biobank for nasopharyngeal carcinoma. Annals of translational medicine. 2020, 10(9): 526.